According to the "Shanghai Release" on September 13th, Chen Jining, Secretary of the Shanghai Municipal Party Committee, met with Zhou Fude, Global President and CEO of Danish Novo Nordisk, and his delegation on September 13th.
We will continue to optimize the business environment, continuously improve the level of marketization, rule of law, and internationalization, and support enterprises to achieve greater development in Shanghai with more efficient docking, higher quality services, and more convenient conditions
Chen Jining introduced the relevant policies and measures to support the development of the biopharmaceutical industry in Shanghai. He said that the Chinese path to modernization we are trying to promote is to make people live a better life and get better health care services. As one of the cities with the highest concentration of life, health, and pharmaceutical research and development in China, Shanghai provides comprehensive and systematic support for the development of the biopharmaceutical industry, including research and development, clinical trials, regulation, production, and insurance. Novo Nordisk is a globally leading pharmaceutical company. We welcome the opportunity to seize the development of the industry, seize the changing demands of the market, and place more innovative research and development, clinical trials, production and manufacturing, and trade logistics in Shanghai. Together with our partners, we aim to achieve win-win development through improving quality and efficiency. We will continue to optimize the business environment, continuously improve the level of marketization, rule of law, and internationalization, and support enterprises to achieve greater development in Shanghai with more efficient connections, better services, and more convenient conditions.
Further optimize the functional layout in Shanghai, expand cooperation space around clinical trials, research and development, production, trade and sales, etc., make innovative drugs more convenient and accessible, and better benefit the vast number of patients
Zhou Fude introduced the company's business and future development plans in Shanghai. He stated that Shanghai is an important city for Novo Nordisk's global layout. The excellent business environment and open policies here are admirable, and the clear direction of supporting the development of the biopharmaceutical industry has strengthened Novo Nordisk's confidence and determination to uphold long-term principles and invest in Shanghai's development. We will further optimize the functional layout in Shanghai, expand cooperation space around clinical trials, research and development, production, trade and sales, etc., to make innovative drugs more convenient and accessible, and better benefit the vast number of patients.
City leader Li Zheng attended the meeting.